Leica Biosystems Recognized as Market Leader in KLAS Digital Pathology 2026 Report
Independent validation matters. This is especially true when it reflects the real experiences of the laboratories and health systems you serve.
In the newly released "KLAS Digital Pathology 2026 US Report," Leica Biosystems has been recognized as a market leader for scanners. At the same time, our partner Indica Labs achieved one of the highest software performance scores* in the 2026 Best in KLAS Awards.
Together, these results tell a powerful story: a digital pathology ecosystem built on high performance hardware and leading image management and analysis software, validated by the voices that matter most, our customers.
What Is KLAS and Why It Matters
KLAS Research is an independent organization that evaluates healthcare technology solutions based on direct customer feedback. It is often compared to a "consumer reports" model for clinical software. KLAS gathers insights through structured interviews with healthcare providers.
These evaluations measure vendor performance across six key customer experience pillars:
- Culture
- Loyalty
- Operations
- Product
- Relationship
- Value
Each vendor receives an overall score on a 100-point scale, reflecting real-world user satisfaction and performance. In digital pathology, KLAS also captures user feedback on associated scanners, providing additional insight into hardware performance.
Aperio GT 450 DX Scanner Recognized for Quality and Throughput
In the 2026 report, the Aperio GT 450 DX scanner from Leica Biosystems was named: "Market Leader for Scanners, Thanks to High Quality & Fast Throughput."
This recognition reflects consistent feedback from laboratories across the United States, with customers highlighting:
- Exceptional image clarity for confident diagnostic review
- High-speed scanning to support faster turnaround times
- Reliable performance in high-throughput clinical settings
Notably, four times more respondents reported using the Aperio GT 450 DX scanner than any other scanner included in the study. This is an important indicator of both market adoption and customer trust.
HALO AP Delivers Top-Tier Software Performance
Equally compelling is the recognition earned by our partner Indica Labs for HALO AP in the 2026 Best in KLAS Awards — Global Software. HALO AP was measured in the Digital Pathology: Europe segment and earned an outstanding overall performance score of 94.9*, with A or A+ ratings across all six Customer Experience Pillars.
What This Means for Pathology Leaders
For organizations navigating digital transformation, independent validation like KLAS provides clarity and confidence.
These findings reinforce a clear takeaway: Leica Biosystems offers a leading digital pathology ecosystem, combining high-performance scanning with top-rated software capabilities.
For laboratories and health systems, this translates to:
- Scalable solutions for increasing case volumes
- Workflow efficiencies across the digital pathology continuum
- Trusted performance supported by independent customer validation
Advancing Digital Pathology with Confidence
As adoption of digital pathology continues to grow, the need for proven, reliable solutions becomes even more critical. Third-party validation plays an important role in helping organizations make informed decisions that impact both operational efficiency and patient care.
“We are proud to be recognized as a market leader in the KLAS Digital Pathology 2026 report, as it reflects the voices and real-world experiences of the laboratories we serve,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “These results underscore the strength of our digital pathology ecosystem—combining high-performance Aperio scanners with best-in-class software through our partnership with Indica Labs—to deliver the speed, quality, and confidence our customers need. As adoption accelerates, we remain committed to driving innovation that is not only advanced, but trusted, scalable, and proven to help improve workflow efficiency and ultimately patient care.”
As long-standing global leaders in digital pathology, Leica Biosystems has a rich history of driving innovation and progress. This enables safe and confident digital pathology adoption through comprehensive, integrated solutions underpinned by a strong evidence base. The KLAS 2026 findings reinforce Leica Biosystems’ commitment to supporting modern pathology laboratories with solutions that are not only innovative, but trusted, scalable, and validated in real world settings.
Learn More about our Digital Pathology Solutions
For In Vitro Diagnostic Use.
*100 point scale; limited data.
Source:
KLAS Research. Digital Pathology 2026 | KLAS Report. Klasresearch.com. Published 2026. Accessed May 20, 2026. https://klasresearch.com/report/digital-pathology-2026-early-adoption-and-technology-performance-in-an-emerging-us-market/3711
KLAS Research. 2026 Best in KLAS Awards - Global Software | KLAS Report. Klasresearch.com. Published 2026. Accessed May 20, 2026. https://klasresearch.com/report/2026-best-in-klas-awards-global-software/3907
Die Inhalte des Knowledge Pathway von Leica Biosystems unterliegen den Nutzungsbedingungen der Website von Leica Biosystems, die hier eingesehen werden können: Rechtlicher Hinweis. Der Inhalt, einschließlich der Webinare, Schulungspräsentationen und ähnlicher Materialien, soll allgemeine Informationen zu bestimmten Themen liefern, die für medizinische Fachkräfte von Interesse sind. Er soll explizit nicht der medizinischen, behördlichen oder rechtlichen Beratung dienen und kann diese auch nicht ersetzen. Die Ansichten und Meinungen, die in Inhalten Dritter zum Ausdruck gebracht werden, spiegeln die persönlichen Auffassungen der Sprecher/Autoren wider und decken sich nicht notwendigerweise mit denen von Leica Biosystems, seinen Mitarbeitern oder Vertretern. Jegliche in den Inhalten enthaltene Links, die auf Quellen oder Inhalte Dritter verweisen, werden lediglich aus Gründen Ihrer Annehmlichkeit zur Verfügung gestellt.
Vor dem Gebrauch sollten die Produktinformationen, Beilagen und Bedienungsanleitungen der jeweiligen Medikamente und Geräte konsultiert werden.
Copyright © 2026 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.